fregime
TODAYSTOCKSARCHIVEABOUTGUIDE
Sign inFollow your stocks

Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

Development · 1 Oct 2026

MEDANTA, full dossier

Global Health has been allotted a land parcel measuring approximately 10,560 sq. metres at Siddharth Vihar Yojna, Ghaziabad, Uttar Pradesh, by the Uttar Pradesh Housing & Development Board for approximately Rs 165.82 crore on a freehold basis.

2 publishers have reported this development. Each act of reporting is below, cited.

The record

Global Health has been allotted a land parcel measuring approximately 10,560 sq. metres at Siddharth Vihar Yojna, Ghaziabad, Uttar Pradesh, by the Uttar Pradesh Housing & Development Board for approximately Rs 165.82 crore on a freehold basis.

capitalmarket.com29 Sep 2026

Global Health Limited has acquired a land parcel in Ghaziabad for approximately Rs 165.82 crore to set up a 350-plus bed hospital.

indiatimes.com29 Sep 2026

Global Health Limited acquired a 10,560-square-metre land parcel in Ghaziabad for approximately Rs 165.82 crore to establish a 350-plus bed hospital.

indiatimes.com30 Sep 2026

Global Health

₹1,357.30

▼ -0.56%

Close (EOD), as of 1 Oct 2026 · source

Global Health: results, dividends, orders, the full cited record →

More on Global Health

Pharma stocks are picking up pace, with the sector continuing to show a strong overall technical setup despite the possibility of short-term profit booking.

2 Oct 2026 · 1 publisher

Medanta's occupancy rose from around 60% in FY22 to approximately 62% in FY26 despite the 47% increase in bed capacity.

18 Sep 2026 · 1 publisher

Delhi Master Plan 2047 introduces several measures that could improve asset productivity and enable higher capacity creation in land-constrained areas for hospital operators.

26 Aug 2026 · 1 publisher

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.